Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 35Recurrence 9Neoplasms 3Sarcoma, Kaposi 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Immunoglobulin Light-chain Amyloidosis 1Chromosome 17 deletion 1Alzheimer Disease 1Acquired Immunodeficiency Syndrome 1

Interventions

pomalidomide 1UE2343 1Dexamethasone 1Amyloid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Alzheimer Disease × pomalidomide × Clear all
NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡